University Hospitals Case Medical Center and Case Western Reserve University School of Medicine to Conduct Innovative Smallpox Vaccine Research StudyJune 04, 2007CLEVELAND: University Hospitals Case Medical Center (UHCMC) and Case Western Reserve University School of Medicine are part of a nationwide research study to determine the safety and effectiveness of a new smallpox vaccine geared toward adults ages 18 to 34 who have never been vaccinated against the disease. The study is the first of its type in Northeast Ohio. The current FDA-approved vaccine, Dryvax®, is not recommended for use on everyone because of the potential for serious side effects in certain individuals. "For example, the current vaccine cannot be used in immune-compromised individuals, such as patients with HIV or individuals with certain skin conditions such as eczema," says Robert A. Salata, M.D., chief of the Division of Infectious Diseases at Case Western Reserve University School of Medicine and UHCMC. The new vaccine, IMVAMUNE®, is different from Dryvax® in that it contains a more weakened form of the live-virus within the vaccine. "Because the vaccine is weakened, the side effects should be minimized enough to give the vaccine to all individuals, even those whose immune systems are suppressed," says Dr. Salata. "Our hope is that the new vaccine will be a safer alternative to the current vaccine." UHCMC and the School of Medicine will act as a subunit of St. Louis University's Center for Vaccine Development, which is one of seven national testing sites known as Vaccine and Treatment Evaluation Units (VTEUs), designated by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The research study, which is actively recruiting and begins here June 15, will follow 215 volunteers nationwide over a two-year period. Volunteers must be in general good health and must not have previously been vaccinated against smallpox. Smallpox is a contagious and sometimes fatal infectious disease characterized by raised bumps that appear on the face and body of an infected person. There is no specific treatment for smallpox disease, and the only prevention is vaccination. The World Health Organization declared the disease eradicated in 1980 with the success of a worldwide vaccination program. Routine vaccination against smallpox among the general public was ceased in 1972 because it was no longer necessary for prevention. However, recent threats of bioterrorism after 9/11 have spurred the development of a new safer vaccine that can be given to immune-compromised individuals. For more information about the study and how to participate, call the Division of Infectious Diseases at 216-368-2003, or e-mail vaccinecenter@case.edu . Additional information can be found under the vaccine research unit link at http://www.cwru.id.org/ Case Western Reserve University |
|||||||||||||||||||||
| Related Smallpox Current Events and Smallpox News Articles Milestone biodefense publication by Elsevier journal Vaccine Last week during the 'Vaccines for Biothreats and Emerging and Neglected Diseases Symposium' in Galveston TX, USA, the Elsevier journal Vaccine released a supplement dedicated to vaccines for biodefense. What are coral reef services worth? $130,000 to $1.2 million per hectare, per year: experts Experts concluding the global DIVERSITAS biodiversity conference today in Cape Town described preliminary research revealing jaw-dropping dollar values of the "ecosystem services" of biomes like forests and coral reefs - including food, pollution treatment and climate regulation. Outfoxing pox: Developing a new class of vaccine candidates In the annals of medicine, Edward Jenner's 1796 vaccination of a young boy against smallpox, using fluid from cowpox blisters, remains a landmark case. In a new study, Kathryn Sykes, a researcher at Arizona State University's Biodesign Institute and her colleagues have taken a fresh look at cowpox. First genetically-engineered malaria vaccine to enter human trials Walter and Eliza Hall Institute scientists have created a weakened strain of the malaria parasite that will be used as a live vaccine against the disease. Study Characterizes Eczema Patients Most at Risk for Dangerous Viral Infections Eczema patients at risk for serious viral infections have more severe disease, are more likely to be allergic to food and other allergens, and have a frequent history of staph infections. Promising antimicrobial attacks virus, stimulates immune system A promising antimicrobial agent already known to kill bacteria can also kill viruses and stimulate the innate immune system, according to researchers at National Jewish Health. La Jolla Institute unlocks mystery of potentially fatal reaction to smallpox vaccine Researchers from the La Jolla Institute for Allergy & Immunology have pinpointed the cellular defect that increases the likelihood, among eczema sufferers, of developing eczema vaccinatum, a severe and potentially fatal reaction to the smallpox vaccine. Scientists discover how smallpox may derail human immune system University of Florida researchers have learned more about how smallpox conducts its deadly business - discoveries that may reveal as much about the human immune system as they do about one of the world's most feared pathogens. Superbug risk to war wounded Soldiers who survive severe injuries on battlefields such as those in Iraq and Afghanistan can be at risk from developing infections of their wounds with multidrug resistant bacteria. DASNR researchers make breakthrough against poxviruses Smallpox has a nasty history throughout the world. Caused by poxviruses, smallpox is one of the few disease-causing agents against which the human body's immune system is ineffective in its defense. More Smallpox Current Events and Smallpox News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||